Racemic drugs are not necessarily less efficacious and less safe than their single-enantiomer components

Practitioners of drug discovery and development of chiral drugs are confronted with the dilemma whether to develop a racemate or a single enantiomer. In 2024, articles were published stating that single enantiomers are clinically more potent than racemates and that the use of single enantiomers instead of racemates improves the effectiveness and/or safety of treatment. The Commentary provides a re…